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 Colitis, an inflammatory bowel disorder, is caused by an array of factors, including 
luminal microbiota alterations and dysregulation of the immune system. Gut microbiota 
produce indole, a compound thought to protect the colon from inflammatory damage. In 
this paper, we explore the effect of indole-3-carbinol, a compound found in many 
cruciferous vegetables, treatment on an ulcerative colitis mouse model with aryl 
hydrocarbon receptor (AhR) depletion in Rorc-expressing immune cells. Indole-3-carbinol 
has been proven to be a ligand for AhR receptors and to reduce inflammation in an 
interleukin-22-dependent manner in female mice. This study explores the same theory but 
with both female and male mice.  
 
ABSTRACT 
 Colitis is an inflammatory bowel disorder (IBD) whose etiology is attributed to 
modification in the luminal microbiota and dysregulation in the immune response. Indole 
is a signaling molecule which is naturally produced by gut luminal microbiota. Indole-3-
carbinol (I3C) is a compound commonly found in vegetables and a ligand for the aryl 
hydrocarbon receptor (AhR). Previous studies have detected decreased expression and 
activation on the AhR receptor in colitis patients, thought to possibly alter gut microbiota 
metabolism, subsequently promoting colitis. 1 AhR, expressed in a variety of immune and 
epithelial cells, contributes to gut homeostasis by affecting vital mediators such as 
regulatory T cell (Treg)/T helper 17 (Th17), colonic epithelial cell (CEC)- regenerating 
interleukin 22 (IL-22) production, and secretion of the protective mucous layer and 
antimicrobial peptides (AMPs) by CECs. I3C in previous experiments has been shown to 
help prevent colitis through induction of IL-22 via innate lymphoid type 3 cells (ILC3s). 
In this study, we investigated how AhR deficiency in Rorc-expressing cells (which we refer 
to as AR mice) affects anti-inflammatory immune response during I3C treatment of colitis, 
whether I3C-AhR interaction in CECs increase IL-22 production during colitis, and the 
effect of AhR deficiency on epigenetic modifications induced by I3C during colitis. A 
dextran sodium sulphate (DSS) colitis mouse model was used in this study to mimic the 
effects of ulcerative colitis and was introduced into drinking water and treatments of I3C 
treatment were given. Results showed compared to wild-type (WT) AR mice induced with 
colitis were unaffected by 13C treatment. In addition, the protective IL-22 production by 
ILC3s was lost for the AR mice. Lastly, we show that I3C treatment does induce epigenetic 
modifications (i.e. DNA methylation) in the promoter region of IL-22. Thus, we conclude 
AhR knockout in Rorc-expressing immune cells mice resist the production of IL-22 via 
ILC3s after I3C treatment during DSS-induced colitis, and loss of this potential protective 
cytokine prevents I3C-mediated beneficial alterations in the gut microbiome.  
 
INTRODUCTION 
Colitis is a disease characterized by 
chronic inflammation in the digestive tract 
and tissue annihilation within the intestinal 
tract. Colitis can progress to form colon 
cancer over a prolonged period, making 
preventative treatments of colitis vitally 
important.2 There are two distinct forms of 
colitis which are defined by the location of 
the inflamed areas and by the depth of 
lesions in the gastrointestinal tissue: 
ulcerative colitis and Crohn’s disease. 
Ulcerative colitis is known to cause 




intestine/colon, only reaching to the 
superficial epithelial surface.3 Crohn’s 
disease exhibits inflammation and typically 
extends deeper into the colonic tissue 
layers.4 The development of colitis is still an 
ambiguous topic but is known to be 
attributed to genetics, environmental 
triggers such as diet, and dysregulation of 
the luminal microbiota and immune 
response.2 
There are two different mouse 
models for inducing colitis, each 
representing a distinct form of colitis, using 
dextran sodium sulfate (DSS) or 2,4,6-
trinitrobenzenesulfonic acid (TNBS).5 The 
DSS induction provides as a model for 
ulcerative colitis since DSS is toxic to 
epithelial colon cells.5 The TNBS induction 
portrays Crohn’s disease since it produces 
an immune response.5 Both models are 
known to exhibit the clinical symptoms of 
weight loss, colon shortening, colon 
damage, and diarrhea/bloody stool. This 
experiment used the DSS colitis model.   
Our lab recently published a report 
using the TNBS model on female mice to 
explore whether the compound I3C, a 
naturally occurring plant product, can be 
effective in preventing colitis and attempted 
to identify the related mechanisms.6 The 
research uncovered that I3C mediates 
inflammation by promoting the production 
of the cytokine, interleukin-22 (IL-22). IL-
22 production is linked to the activation of 
the aryl hydrocarbon receptor.6 These new 
findings are expanded on in this paper since 
this paper describes a nearly identical 
experiment, except using the DSS model 
and mice with AhR conditionally knocked 
out in Rorc-expressing immune cells, which 
are known to produce IL-22.  
 The aryl hydrocarbon receptor 
(AhR) is a cytosolic-bound intracellular 
receptor, meaning that the receptor is 
located in the cytoplasm until activated by a 
ligand.7 Once the ligand has bound to the 
receptor, the receptor is able to translocate 
to the nucleus, heterodimerizes with aryl 
hydrocarbon receptor nuclear translocator 
(ARNT) and mediate gene transcription of 
AhR-responsive genes. The gene 
transcription mediation by the AhR receptor 
helps regulate liver detoxification and 
immune cell regulation.7 As a result, the 
AhR receptor can be found in a variety of 
cell types, including immune cells and 
colonic epithelial cells.7 Interestingly, 
previous research has discovered patients 
suffering from colitis typically have a 
decrease in expression of AhR in lamina 
propia (LP) mononuclear cells.8 
I3C is a likely candidate for 
treatment of colitis since it is a known 
ligand for AhR.9  I3C already has a number 
of known therapeutic advantages thus far, 
such as anti-cancer, antioxidant, anti-
microbial, and anti-inflammatory effects.10 
I3C’s anti-inflammatory effects are thought 
to be attributed to it driving IL-22 
production, which promotes epithelial cell 
regeneration and maintaining mucosal 
barrier integrity.6 IL-22 can be expressed by 
many cell types, including T helper cells 
(Th17/Th22) and innate lymphoid Type 3 
cells (ILC3).11 This experiment attempts to 
determine the mechanism which I3C 
undergoes when acting as an anti-
inflammatory agent by studying how AhR 
deficiency in Rorc-expressing immune cells 
(i.e. ILC3s) affects treatment of colitis. 
There were six experimental groups used in 
this experiment as a result: LM+Vehicle, 
AR+Vehicle, LM+I3C, AR+I3C, 
LM+Colitis, AR+Colitis, LM+Colitis+I3C, 
and AR+Colitis+I3C.  
This experiment is able to quantify 
the number of IL-22 expressing immune 
cells by conducting a staining panel for 
labeling biomarkers distinct to T cells and 
ILC3 cells; the lineage monoclonal 
antibodies CD45+Lin-CD90.2+Rorgt are 




Since IL-22 production is already known to 
be increased by I3C treatment, and I3C is 
known to be related to DNA transcription 
through AhR, this experiment also 
examines the methylation patterns of 
experimental mice. Increased methylation 
indicates decreased transcription; decreased 
methylation indicates increased 
transcription. Thus, an increase in 
methylated DNA would suggest a decrease 
in AhR receptors or a decrease in 13C.  
There is no definitive cure for colitis 
and traditional drug treatments induce many 
side effects. Glucocorticoids, for example, 
can cause a variety of alterations in the liver 
and pancreas.12 These patients are 
recommended to have their blood checked 
regularly by their doctor for signs of these 
possible side effects. This study examined 
blood samples from each experimental 
mouse at the end of the trial, in order to 





Male and female C57BL/6J mice 
were purchased from Jackson Laboratory, 
and experimental mice used were between 
the age of 8 to 10 weeks, at the average 
weight of 15-18 grams. The breeding pairs 
included Ahr-flox (Ahrtm3.1Bra/J) bred 
with a Rorc-cre (B6.FVB-Tg(Rorc-
cre)1Litt/J). The mice were housed at the 
Association for Assessment and 
Accreditation of Laboratory Animal Care-
accredited (AAALAC-accredited) animal 
facility in the University of South Carolina 
School of Medicine, Columbia. The 
facilities offered precise pathogen-free 
conditions, with 12-hour light/12-hour dark 
cycles.  
This experiment required the use of 
six distinct experimental groups. The 
littermate mice (LM) served as controls in 
comparison to the AR mice. The groups for 
the experiment were LM+Vehicle, 
AR+Vehicle, LM+I3C, AR+I3C, 
LM+DSS, AR+DSS, LM+DSS+I3C, and 
AR+DSS+I3C.  
 
Generation of mice lacking AhR in Rorc-
expressing cells (AR mice) 
The cre-flox recombination 
technique was used in our lab to generate 
mice lacking AhR in Rorc-expressing 
immune cells. AhR-floxed (AhRf/f) mice 
were bred with Rorc(t)-cre mice to 
produce AhR knockout (KO) mice in T 
cells/ILC3s, named AR mice. Each mutant 
transgene mouse was genotyped using PCR 
to ensure the conditional deletion from 
DNA, as seen in Figure 1. The DNA was 
isolated from the tissue via tail snips (≤25 
mg). The DNA was isolated from the tail 
snips using the DNeasy Blood & Tissue Kit 
(cat. nos. 69504 and 69506) from Qiagen. 
Once the DNA was isolated, gel 
electrophoresis was then used to validate 
the mutant DNA using primers specific to 
detect the mutant strains. TAE (trise-
acetate-EDTA) buffer (VWR) was used 
with agarose (VWR) to create a standard 
1.5% agarose gel. Approximately 1.5 g of 
agarose was missed with 100 mL of TAE in 
a microwaveable flask and then 
microwaved for 1-3 minutes, or until the 
agarose was completely dissolved. Once 




cooled, approximately 2-3 𝜇l of ethidium 
bromide (Sigma-Aldrich), EtBr, was added 
to the mixture. Ethidium bromide would 
bind to the DNA and was essential for 
visualizing the DNA under ultraviolet (UV) 
light. The mixture was then poured into the 
casting tray of the gel box with the well 
comb already in place. The poured gel was 
then left to sit at room temperature for 20-
30 minutes, or until it had fully solidified. 
Once solid, the agarose gel was placed in 
the gel box, the gel box was filled to TAE 
until the gel was covered, and a voltage 
source was then attached to the electrodes. 
The loading buffer, 1X TAE buffer (Sigma-
Alder) was added to each of the DNA 
samples and the samples were then 
carefully loaded into the wells of the gel. 
The gel was run at 80-150 V for 
approximately 1 hour. The electrodes were 
removed, and the gel was carefully removed 
from the gel box. The gel was placed under 
a UV light (Universal Hood li Molecular 
Imager with Camera, Bio-Rad) which 
allowed for the DNA fragments to be 
visualized. The control counterparts to the 
mutant mice were controlled, or littermate 
(LM), mice.  
 
Induction of colitis and treatment with I3C 
The DSS used for this experiment 
was purchased from MP Biomedical LLC. 
and was colitis grade. DSS model colitis 
was induced in 4 of the experimental groups 
through drinking water (Figure 2). The 
drinking water contained 3% DSS for 6 
days, which was followed by 8 days of 
normal drinking water. Previous 
experiments have proven 1 week of DSS 
treatment is sufficient for effectively 
inducing an ulcerative colitis model.13 
There were 3 experimental groups who 
received I3C treatment. For the treatment 
groups with DSS colitis model, mice were 
given injections of 40 mg/kg in 0.05% 
DMSO/corn oil starting 1 hour after the 
administration of the DSS water and 
continued every other day until the end of 
the experiment. LM groups were also given 
0.05% DMSO/corn oil injections every 
other day.  
 
Assessment of colitis disease parameters 
Clinical parameters for colitis were 
measured and examined throughout the 
entirety of the experiment. The mice were 
weighed daily using a scale (ALC-2100.1, 
Acculab), in order to determine the percent 
weight loss over the duration of the trial. 
Colonoscopies were also performed to 
assess tissue damage. At experimental 
endpoints, the mice were euthanized using 
isoflurane overdose. After the trial 
completion, the lengths of the colons were 
measured. Serum (~10 microliters) was 
analyzed using a VetScan (Allied Analytic) 
to determine diagnostic blood panel 
percentages, as outlined in Figure 3. Figure 2. Summary of DSS colitis model with 
I3C treatments. Colitis was induced using a DSS 
model and the effectiveness of the I3C treatments 
were tested with the following experimental groups 
unless otherwise stated: LM vehicle (n=7), LM I3C 
(n=5), LM DSS+vehicle (n=7), LM DSS+I3C 





Lamina propria layer isolation and immune 
cell validation using flow cytometry 
 Flow cytometry was used to explore 
the effects on immune cell response when 
AhR was depleted in Rorc-expressing cells. 
Cells from the lamina propria (LP) were 
isolated by removing and cleaning the 
intestine of a 6-10-week-old C57BL/6 
mouse using PBS (VWR). The intestines 
were placed into 50 mL conical tubes 
(VWR) with 15 mL of pre-digestion buffer 
(VWR) and incubated. The colons were 
then cut laterally (~0.5 cm pieces) and 
incubated for 40 minutes at 37oC under a 
continuous rotation. Once incubated, the 
samples were vortexed for 10 seconds and 
applied onto a 100 𝜇m cells strainers 
(VWR) having been placed on a 50 mL 
tube. The samples were then transferred 
into a new 50 mL tube containing 20 mL of 
HBSS (VWR) and incubated at 37oC for 10-
20 minutes under a continuous rotation. The 
samples were then vortexed for another 10 
seconds to ensure they were mixed well and 
applied onto a MACS SmartStrainer, 100 
𝜇m, and placed in a 50 mL tube.  
The intestine tissue was then 
transferred into the gentle MCS C tube 
which contained the digestion buffer and 
the tube was sealed tightly. The sample was 
then incubated again for 30-75 minutes at 
37oC under continues rotation. The C tube 
was the attached nupside down to the sleeve 
of the gentleMACS Dissociator (Miltenyi 
Biotec) and the gentleMACS was run. Once 
the program was complete, the tube was 
detached from the Dissociator and a short 
spin (up to 300xg) was completed in order 
to collect the sample from the bottom of the 
tube. Another 5 mL of complete RPMI 
media (VWR) was added, and the cell 
suspension was applied to a 100 𝜇m cell 
strainer, inserted in a 50 mL tube. The 100 
𝜇m strained was washed with 10 mL of PBS 
with 3% FBS (FACS Buffer, VWR) and the 
strainer was then discarded.  
The cell suspension was centrifuged 
at 1300 rpm for 10 minutes at 40oC. We 
resuspended the cells in 10 mL of FACS 
buffer and a layer on 5 mL of 90% Percoll, 
having been diluted using 10x PBS (VWR). 
The samples were then spun at 2000 rpm for 
15 minutes at room temperature and 
resuspended in 10 mL FACS. We spun the 
samples again at 1300 rpm for 10 minutes 
at 40oC and resuspended in 1 mL of RBC 
lysis buffer on ice for 2 minutes. Once 
chilled, 10 mL of FACS was added and the 
samples were spun at 1300 rpm for 10 
minutes at 40oC and resuspended in 2 mL of 
FACS. An automated cell counter (Bio-
Rad) was used to record the cell count and 
viability.  
Once the cells were isolated from 
tissue, they were stained with fluorescent 
antibodies, indicators of IL-22-producing 




cells. The cells were then passed through 
the FACS Celesta flow cytometer (BD 
Biosciences). The gating and the analysis of 
flow plots were performed using FlowJo 
version 10.5.3 (BD Biosciences). Two 
specific immune cells were stained in the 
flow cytometry: ILC3 (CD45+Lin-
CD90.2+Rorgt+) and Th22 (CD3+CD4+IL-
17-).  
Determination of DNA methylation status 
 The DNA methylation patterns were 
examined to determine the effects of I3C 
treatments on transcription in the DSS-
model of ulcerative colitis. A genome-wide 
DNA methylation was conducted using 
methylated DNA immunoprecipitation 
sequencing (MeDIP-seq) on cells isolated 
from CD45+ immune cells from the lamina 
propria of experimental groups 
(DSS+Vehicle and DSS+I3C). MeDIP-seq 
was performed as previously described.14 
 
Statistics 
All statistical analysis   were 
conducted using GraphPad Prism software 
unless otherwise indicated. A 1-way 
ANOVA and Tukey’s hoc multiple 
comparisons tests were used to determine 
the statistical significance when comparing 
3 or more groups. A 2-way ANOVA and 
Turkey’s hoc multiple comparisons tests 
were used to determine the statistical 
significance when comparing 3 or more 
groups with more than one data point. For 
comparisons between only two groups, an 
unpaired, 2-tailed standard Student’s t-test 
was used. A P value less than 0.05 was 
considered significant.  
 
Study approval 
All procedures conducted involving 
the use of mice obey NIH guidelines under 
protocols approved by the IACUC at the 
University of South Carolina School of 
Medicine (Columbia).  
 
RESULTS 
Treatment with I3C and/or DSS does not 
effect blood work diagnostics  
We conducted a full blood panel on 
each of the mice at the end of the 
experiment. The blood panel determined 
the white blood cell (WBC) count and the 
percent of lymphocytes, monocytes, and 
neutrophils, as illustrated in Figure 4. The 
white blood cell count provides 
information on the immune system since 
they aid the body to fight infection and 
disease.  Lymphocytes are what determine 
the specificity of the immune response to 
infection and disease. Monocytes aid other 
WBC to remove dead or damaged tissues, 
Figure 4. AhR defficiancy in Rorc-expressing immune cells resulted in no effect on blood work. 
Blood was collected from experimental mice and run on a VetScan to access, White blood cell (WBC) 
count, lymphocyte percent, monocyte percent, and neutrophil percent. Significance was determined using a 
1-way ANOVA and Tukey’s multiple comparisons tests. There was found to be no significant differences 




kill cancer cells, and regulate immunity 
from infection and disease. Neutrophils are 
the first immune cells to respond to a 
foreign pathogen and are responsible for 
the destruction of the microorganism or 
molecule.  
Previous results from our have 
proven that neither the I3C treatment does 
not affect blood-circulated immune cells 
like the white blood cell count and percent 
of lymphocytes, monocytes, and 
neutrophils, which play a role in the 
immune response. To that end, we studied 
mice with AhR deficiency in Rorc-
expressing immune cell, in comparison to 
the four control groups, and found no 
statistically significant differences, 
suggesting the major immune cell 
differences are localized in the colon.  
 
AR mice with I3C and DSS treatments 
loose I3C-mediated beneficial effects  
For the purpose of testing the 
efficacy of I3C treatment in the DSS colitis 
model, mice with colitis were treated with 
an I3C regime that has been  effective in 
Figure 5. I3C treatment failed to protect against DSS-induced colitis in both AR mice. The 
parameters assessed for quantifying the disease was (A) percent weight loss, (B) colon length, and (C) 
Representative colonoscopy images were taken during day 7 of the DSS model (n=5). Scale bars: 100 
micrometers (original magnification, x100). Significance was determined using a 1-way ANOVA and 
Tukey’s multiple comparisons tests for the colon lengths and macroscopic colitis score and a 2-way 





treating other forms of inflammatory 
diseases.15  We used 6 experimental groups 
of mice: vehicle alone (LM vehicle), I3C 
treatments alone (LM I3C), diseased alone 
(LM DSS+Vehicle), diseased receiving I3C 
treatment (LM DSS+I3C), diseased mutant 
(AR DSS+Vehicle), and diseased mutant 
receiving I3C treatment (AR DSS+I3C). 
The percent weight loss was determined 
each day of the experiment from the start 
(Figure 5A). We observed a significant 
percent weight loss in the LM 
DSS+Vehicle, the AR DSS+Vehicle, and 
the  AR DSS+I3C (Figure 5A). The percent 
weight loss was slightly reduced for the LM 
DSS+I3C (Figure 5A). Whereas, the LM 
Vehicle and the LM I3C experienced no 
significant weight loss (Figure 5A), which 
suggested AR mice no longer responded to 
I3C like the LM controls. Next, we 
measured the colon lengths at the end of the 
experiment (Figure 5B). Mice induced with 
DSS colitis receiving I3C treatment 
experienced a reduction in their colon 
(~1.25 cm) compared to the control groups, 
LM vehicle and LM I3C (Figure 5B). A 
significant reduction in the colon lengths 
were found in the LM DSS+Vehicle group 
(~2.5 cm), the AR DSS+Vehicle group 
(~3.0 cm), and the AR DSS+I3C group 
(~2.5 cm). No statistical significant 
difference was found in the colon lengths  
between the diseased mutant mice and the 
diseased mutant mice receiving treatment.  
Colonoscopy images revealed that 
the diseased mutant mice receiving 
treatment had evidence of ulcerations and 
tissue annihilation through the lining of the 
colon, whereas the observations from the 
diseased LM receiving treatment exhibited 
far less destruction (Figure 5C). The 
diseased vehicle mice, mutant diseased 
mice, and the mutant diseased mice 
receiving I3C treatment displayed 
Figure 6. IL-22 secretion by Th22 cells is unaffected in diseased AR mice. (A) Percent of IL-
22 producing Th22 cells. (B) Representative flow charts for each experimental group. Scale 
bars: 100 micrometers (original magnification, x100). Significance was determined using a 1-





significantly increased colon damage in 
comparison to the controls, LM Vehicle and 
LM I3C (Figure 5C). Taken altogher, it 
appeared that AR mutants lost the ability to 
respond to I3C treatment, unlike their LM 
counterparts. 
 
I3C-mediated increase of IL-22 secreted 
by T cells is not altered in diseased AR 
mice  
 The expression of IL-22 producing 
Th22 cells in each experimental group was 
determined using flow cytometry and 
staining for CD4, a biomarker for T helper 
cells. The percentages indicated in the 
bottom left corner of each flow chart 
provides a numerical value for comparison 
of experimental groups based on levels of 
CD4 expressing IL-22. The higher the 
percentage, the greater the cells expression. 
The flow charts depict LM+Vehicle mice 
intensity as 3.58, 2.89 for LM+I3C, 14.6 for 
LM+DSS+Vehicle, 11.4 for 
LM+DSS+I3C, 12.4 for 
AR+DSS+Vehicle, and 10.8 for 
AR+DSS+I3C mice (Figure 6B). The 
percent of IL-22 producing Th22 cell was 
also determined for each experimental 
group based off of the flow cytometry data. 
We found no statistically significant 
difference in the percent of Th22 cells 
between the diseased AR mutant receiving 
treatment and diseased LM mice receiving 
I3C treatment (Figure 6A), thus suggesting 
AhR on Rorc-expressing immune cells does 
not alter IL-22 production by Th22 cells.  
 
I3C-mediated increase of IL-22 secreted 
by ILC3 cells is prevented in diseased AR 
mice  
 Flow cytometry was also used for 
exploring whether the quantity of ILC3 
cells in the lamina propria is affected by 
AhR depletion in immune cells (AR mice). 
The flow cytometer determined the percent 
of IL-22 synthesizing ILC3s (Figure 7A) 
Figure 7. IL-22 secretion by ILC3 cells is prevented in diseased AR mice. (A) Percent of IL-22 
producing ILC3 cells. (B) Representative flow charts for each experimental group. Scale bars: 100 
micrometers (original magnification, x100). Significance was determined using a 1-way ANOVA 





and revealed a representative bar chart 
(Figure 7B). The representative bar charts 
quantify the area of the shaded region, as 
seen in the bottom right corner of each flow 
plot. Thus, larger area values indicate an 
increased number of IL-22 producing 
ILC3s identified using the fluorescent 
markers. The bar charts depict percent 
quantification of the ILC3s (CD45+Lin-
CD90.2+Rorgt+) producing IL-22. 
 It should be noted that the intensity 
value indicated by the flow charts for 
LM+Vehicle can be found as 20.6, 22.8 for 
LM+I3C, 18.4 for LM+DSS+Vehicle, 65.3 
for LM+DSS+I3C, 20.9 for 
AR+DSS+Vehicle, and 27.2 for 
AR+DSS+I3C mice (Figure 7B). The data 
shows that in disease LM mice treated with 
I3C there was a significant increase in IL-
22 production, which we had previously 
shown. However, disease AR mice treated 
with I3C did not show an increase in IL-22 
production in ILC3 cells, which suggests 
that this increase in protective IL-22 by this 
immune cell subset was dependent on AhR 
expression. 
 
Treatment of I3C decreases methylation of 
IL-22 promoter region in diseased mice 
This experiment also sought to 
begin investigating I3C-mediated 
epigenetic modifications, DNA methylation 
specfically, involved in IL-22 regulation. 
The lab plans on exploring these epigenetic 
modifications further in future studies with 
AhR conditional knockout mice. DNA 
methylation is of great significance since it 
is relates to the frequency which the gene is 
being transcribed. Samples from the two 
diseased wild-type (WT) experimental 
groups, WT DSS+Vehicle and WT 
DSS+I3C, were used for MeDIP-seq, and 
methylation patterns were determined  for 
the IL-22 promoter region of the DNA 
(Figure 8). The DNA methylation of the 
diseased mice receiving I3C treatment was 
found to be significantly decreased in 
comparison to the diseased mice not 
receiving treatment. This suggests that one 
of the mechanisms by which I3C increases 
IL-22 production is by decreasing DNA 




 Research and new development of 
safe preventative treatments  to inhibit  
colitis are of great importance. Studies have 
shown chronic inflammation through the 
intestine to be linked to alterations in the 
luminal microbiota and to dysregulation of 
the immune system.6 There is an increasing 
consensus that AhR plays a prominent role 
in regulating the immune system through 
the intestine.16 AhR has been shown in 
promote the production of interleukin-22 
(IL-22) once activated by a ligand.17 
However, the mechanisms which AhR 
primarily uses to regulate the immune 
system in the gut microbiome is still 
Figure 8. I3C decreases DNA methylation in 
promoters of IL-22 regulatory genes during DSS-
induced colitis. DNA methylation was determined 
using MeDIP-seq, as described in the Methods. The 
IL-22 promoter region can be found in the figure 
highlighted green. The methylation patterns of 
DSS+Vehicle (bottom) and DSS+I3C (top) samples 




unknown. There appears to be a link with 
the expression of AhR in Rorc-expressing 
immune cells that occur during colitis and 
the expression of IL-22, which is 
demonstarted further by this study. 
 The DSS-induced diseased mutant 
AR mice lost all protective benefits of I3C 
treatments. The diseased AR mice proved to 
have no statistically significant difference 
in their percent weight loss, colon lengths, 
and macroscopic score when receiving I3C 
treatment. Whereas, the diseased littermate 
mice showed a significant improvement and 
increase in their percent weight loss and 
colon length when receiving I3C treatment. 
The representative colonoscopy images 
display the healing affects of I3C through 
the colon when comparing the diseased LM 
mice to the diseased LM mice receiving 
treatment. However, the colonoscopy 
images of the diseased mutant AR mice 
receiving I3C treatment revealed evidence 
of ulcerations and tissue destruction in the 
lining of the colon, which was just as severe 
as those found in the diseased mutant mice 
not receiving treatment.  
 As noted before, I3C is a recognized 
ligand of AhR. Recent reports have shown 
I3C to have a protective effect by improving 
the necroptosis and inflammation of 
intestinal epithelial cells by activating AhR 
in mice with DSS-induced colitis.18 In this 
current study, AhR activation was 
examined in Rorc-expressing immune cells. 
There also has become an increasing 
consensus that upon activation the AhR 
receptor, there is an increased regulation of 
IL-22, helping restore the gut 
homeostasis.19 Thus, this study has further 
proven that without an abundance of AhR 
receptors, I3C has nothing to bind to, which 
results in no production of IL-22, at least in 
ILC3s. Similar reports have found ILC3s 
production of IL-22 to change upon I3C 
treatment.6 
Of particular note was the fact that 
secretion of IL-22 by ILC3 cells was 
prevented in AR mutant mice receiving I3C 
treatment. This was a important finding 
because AhR can be found in many 
different types of cells; however, it has 
remained unclear as to which cell type 
promotes gastrointestinal thereuputic 
benefits via AhR activation. This study 
revealed an increase in IL-22 secreting 
ILC3 cells when diseased LM mice were 
given I3C treatments. However, the 
diseased mutant mice with a depletion of 
AhR in Rorc-expressing immune cells 
displayed no increase in IL-22 producing 
ILC3 cells when receiving I3C treatments, 
proving AhR was essential for this I3C-
mediated effect.  
In comparison, the T helper type 22 
(Th22) cells were unaffected by a depletion 
of AhR receptors. This would suggest that 
the AhR receptor primarily use IL3C cells 
over Th22 cells. We concluded that the AhR 
receptor primarily translocates in ILC3 cells 
when producing IL22. Other recent reports 
have shown collectively that ILC3 cells are 
responsible for regulating gastrointestinal 
mucosal homeostasis via controlled 
generation of IL-22 and IL-17.20 
Interestingly enough, studies have also 
shown the frequency of ILC3s  to be 
decreased in inflamed tissue.21 
The methylation patterns of the 
DSS-induced colitis diseased mice 
recieving I3C treatment revealed a decrease 
in methylation, when compared to the 
diseased mice not receiving treatment. The 
reduced methylation implies that there is a 
increase in the transciption of the IL-22 
gene. An increase in transciption would 
result in an increase in creation of the 
cytokine IL-22, which helps reduce and 
control inflammation.22 Other reports have 
recently suggested a protein coding gene, 




receptor of ILC3 which triggers tissue 
repair upon colon damage.23  
The study’s findings are consistent 
with the theory that DSS-induced diseased 
mice when treated with I3C are able to 
manage chronic inflammation and tissue 
damage through production of IL-22. In 
conclusion, these studies revealed that I3C 
mediated protection against colitis was 
heavily dependent on AhR expressed in 
Rorc-expressing immune cells, such as 
ILC3s. Without AhR expression, protective 
IL-22 was no longer produced after I3C 
treatment of colitis, thus negating the 
beneifical effects observed in LM controls.
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